Tag Archive for: Series C

Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round,  which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376.

The company has several targeted therapeutics in early-stage trials and preclinical development for cancer types with high expression levels of the protein.